Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NNC9204-1706 · 1 trial · 2 indications
Count of adverse events.
| Arm | Type | Description |
|---|---|---|
| NNC9204-1706 | EXPERIMENTAL | Participants will receive NNC9204-1706 for 10 weeks. There will be a 2-week follow-up period after the treatment period. |
| Placebo (NNC9204-1706) | PLACEBO_COMPARATOR | Participants will receive placebo (NNC9204-1706) for 10 weeks. There will be a 2-week follow-up period after the treatment period. |
| Name | Type | Description |
|---|---|---|
| NNC9204-1706 | DRUG | Participants will receive NNC9204-1706 subcutaneous (s.c., under the skin) injection(s) once daily (OD) for 10 weeks. They will either receive the same dose throughout the trial, or the dose will be escalated over a period of 1-3 weeks and continued for at least 7 weeks at the same dose. |
| Placebo (NNC9204-1706) | DRUG | Participants will receive matching placebo (NNC9204-1706) s.c., injection(s) OD for 10 weeks. |
Inclusion Criteria: * Male or female, aged 18-55 years (both inclusive) at the time of signing informed consent. * Body mass index (BMI) between 25.0 and 39.9 kg/m\^2 (both inclusive) at screening. Overweight should be due to excess adipose tissue, as judged by the investigator. Exclusion Criteria...
NNC9204-1706 is an investigational small molecule being developed by Novo Nordisk for the treatment of metabolism and nutrition disorders, specifically overweight and obesity. It is currently in Phase 1 clinical development and is not yet approved by regulatory authorities.
The molecular target of NNC9204-1706 has not been disclosed in available information. The drug is being studied for its effects on metabolism and nutrition disorders, including obesity, but its specific mechanism of action is not publicly detailed.
NNC9204-1706 is being developed by Novo Nordisk A/S, a pharmaceutical company listed on the stock exchange under the ticker symbol NVO. The company is conducting clinical research to evaluate the drug's safety and efficacy in people with overweight or obesity.
NNC9204-1706 is in Phase 1 clinical development. A Phase 1 trial has been completed, and the drug remains investigational, meaning it has not been approved for commercial use. Further clinical studies would be needed to assess its potential for regulatory approval.
NNC9204-1706 has been studied in one completed Phase 1 clinical trial with the identifier NCT03661879. This trial, titled 'Research Study of a New Medicine (NNC9204-1706) in People With Overweight or Obesity,' enrolled 60 participants in the United States and was randomized, double-blind, and placebo-controlled.
No alternative names for NNC9204-1706 have been disclosed in available information. The drug is identified solely by its code name NNC9204-1706 in clinical trial registries and public records.